arrow
D

Dimitra Rafailia Bakaloudi

UCSF Helen Diller Family Comprehensive Cancer Center
H指数:18
被引数:1,864

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study

在恩沃利单抗之后的尿路上皮癌患者中,萨cituzumab govitecan的疗效:UNITE研究的分析

2025-12-010
OAAI
Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort study

膀胱癌亚型组织学患者中经尿道膀胱肿瘤切除术与根治性膀胱切除术病理结果的一致性:一项回顾性队列研究

2025-11-010
PRE
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study

FGFR3突变型晚期尿路上皮癌中,erdafitinib在enfortumab vedotin治疗前或治疗后的疗效:UNITE协作研究的分析

2025-11-010
PRE
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study

接受恩沃利单抗维多汀治疗的晚期尿路上皮癌患者中的治疗相关不良事件及关联结局:UNITE研究的分析

2025-10-020
OAAI
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study

恩福妥单抗(Enfortumab Vedotin)在具有不同组织学亚型的晚期尿路上皮癌患者中的疗效:UNITE研究的分析

2025-09-140
PRE
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data

与恩夫妥单抗韦汀疗效相关的基因组生物标志物:对UNITE研究数据的分析

2024-12-011
OAAI
Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE

恩沃利单抗 vedotin(Enfortumab vedotin)诱导的外周神经病变(EVIPN)在晚期尿路上皮癌(aUC)患者中的预处理(Tx)危险因素:UNITE 分析

2024-09-010
PRE
Enfortumab vedotin (EV) plus pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients (pts) with advanced urothelial carcinoma: Analysis of the UNITE study

恩福妥单抗(EV)联合帕博利珠单抗(P)在临床试验外的疗效及在晚期尿路上皮癌患者(pts)中的获益生物标志物:UNITE研究的分析

2024-09-010
PRE